Completed PHASE2 INTERVENTIONAL 4-arm NCT01001195

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Sponsor: Allergan

Conditions Glaucoma, Open-Angle Ocular Hypertension

Interventions AGN-210669 ophthalmic solution, 0.05% AGN-210669 ophthalmic solution, 0.075% AGN-210669 ophthalmic solution, 0.1% bimatoprost ophthalmic solution 0.03%

Updated 8 times since 2017 Last updated: Aug 13, 2013 Started: Nov 30, 2009 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01001195, this PHASE2 trial focuses on Glaucoma, Open-Angle and Ocular Hypertension and remains completed. Sponsored by Allergan, it has been updated 8 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States